What is Oruka Therapeutics, Inc.'s stock issuance proceeds?

Oruka Therapeutics, Inc. (ORKA) reported stock issuance proceeds of $1.7M in Q1 2026.

What does stock issuance proceeds mean?

Refers to the total cash inflows received from the sale of common equity shares to investors. This metric reflects the company's ability to raise capital through equity markets to fund research, development, or general corporate purposes.

Oruka Therapeutics, Inc. ORKA Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Oruka Therapeutics, Inc.ORKA

$1.7M—

HWK

HawkinsHWKN

$760K+14.4%

SkyWestSKYW

$1.31M+1.5%

StepStone Group Inc.STEP

$1.95M+38.6%

Atmos EnergyATO

$199.62M—

Cherry Hill Mortgage InvestmentCHMI

$165K-95.4%

Other financials

Income statement

See full

Revenue-—

Operating income-$36.4M-45.2%

Net income-$31.8M-51.5%

EPS (diluted)-$0.46+93.4%

Balance sheet

See full

Cash & equivalents$49.5M-40.7%

Total debt$1.8M+90.8%

Total equity$486.7M+33.4%

Total assets$504.5M+33.8%

Cash flow

See full

Operating cash flow-$23.6M-13.0%

CapEx$73.0K+462%

Free cash flow-$23.7M-13.3%

Valuation

See full

Market cap$5.03B+533%

Returns & leverage

See full

Return on equity-27.3%-11.1pp

Debt / equity0×0.0×

Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s stock issuance proceeds?: Oruka Therapeutics, Inc. (ORKA) reported stock issuance proceeds of $1.7M in Q1 2026.
What does stock issuance proceeds mean?: Refers to the total cash inflows received from the sale of common equity shares to investors. This metric reflects the company's ability to raise capital through equity markets to fund research, development, or general corporate purposes.